FORTUNE and Great Place to Work Name Second Genome a "Top 10 Best Workplace in Biopharma"
April 10, 2019, South San Francisco, CA
SOUTH SAN FRANCISCO, Calif., April 9, 2019 -- FORTUNE and Great Place to Work have honored Second Genome as one of the 2019 Top 10 Best Workplaces in Biopharma. The ranking considered feedback representing almost 730,000 employees working at Great Place to Work-Certified organizations in the health care and biopharma industry. Great Place to Work, a global people analytics and consulting firm, evaluated more than 60 elements of team members' experience on the job. These included the extent to which employees trust leaders, the respect with which people are treated, the fairness of workplace decisions, and how much camaraderie there is among the team. Rankings are based on employees' feedback and reward companies who best include all employees, no matter who they are or what they do for the organization.
"We are thrilled that our employees placed us in the top 10 biopharmaceutical companies within the United States," said Karim Dabbagh, Ph.D., CEO of Second Genome. "Strong cultures lead to business success. The more empowered our employees feel, the bigger impact they have on our mission: to develop proprietary, first-in-class compounds inspired by the microbiome for patients with cancer, gastrointestinal diseases and other disorders."
"This honor reflects the fact that our employees drive our culture, creating an environment where they feel valued," said Jim Sjoerdsma, Executive Vice President of Human Resources. "We all know that we each have an impact on the team culture. Our company culture inspires our employees to work in a committed way, to bringing all their talents into play in the workplace."
Second Genome placed 10 on the list, with the full list below:
- United Therapeutics Corporation
- Horizon Pharma plc
- Regeneron Pharmaceuticals, Inc.
- Novo Nordisk Inc.
- Tec Laboratories, Inc.
- Takeda Pharmaceuticals
- Second Genome
"Healthcare and Biopharma companies are exposed to increasingly complex and rapidly changing environments," said Michael Bush, CEO of Great Place to Work. "The Best Workplaces on this list stand out for cultivating agile workplaces with increasingly change-ready employees. People in these workplaces feel well-informed, encouraged to offer meaningful improvements, and are supported by leaders that are trustworthy, transparent and collaborative."
About the Best Workplaces in Health Care & Biopharma
Great Place to Work based its ranking on a data-driven methodology applied to anonymous Trust Index™ survey responses from more than 95,000 employees at Great Place to Work-Certified organizations in Financial Services & Insurance.
About Great Place to Work
Great Place to Work is the global authority on high-trust, high-performance workplace cultures. Great Place to Work recognizes outstanding workplace cultures and produces the annual Fortune "100 Best Companies to Work For®" and Great Place to Work Best Workplaces lists for Millennials, Women, Diversity, Small & Medium Companies, industries and, internationally, countries and regions.
About Second Genome
Second Genome is a clinical-stage company focused on discovering and developing therapeutics identified using microbiome science. The company is evaluating SGM-1019 in a Phase 2 clinical trial in patients with NASH, moving into IND-enabling studies for a second clinical candidate involved in mucosal healing, and has a pipeline of discovery candidates in the area of immuno-oncology. The deep pipeline results from Second Genome's robust drug discovery platform, which elucidates and interrogates important microbial (microbiome) functions that strongly influence human health and disease, and serves as the basis for therapeutic discovery. Central to this platform is the world's largest, dynamic, curated database and a suite of software, hardware and data science capabilities that allows Second Genome to accurately identify microbial biology in health and disease. For more information, please visit www.secondgenome.com.
SOURCE Second Genome, Inc.